Lymphatic and Blood Network Analysis During Obesity

Summary

Obesity is a growing global public health issue. It has been previously associated with lymphatic dysfunction, suggesting a vital crosstalk between the adipose tissue and the lymphatic system. Here, we propose an accessible methodology allowing the distinct labeling of blood and lymphatic vasculatures within the subcutaneous adipose tissue.

Abstract

Lymphatic collecting vessels and lymph nodes are inevitably embedded in adipose tissue. The physiological significance of this observation remains still not elucidated. However, obesity is characterized by impaired lymphatic function and increased vessel permeability. Inversely, lymphatic dysfunction induces obesity in mice, suggesting a significant interplay between lymphatic vessels and the adipose tissue. Therefore, understanding factors leading to lymphatic dysfunction might open new therapeutic windows to prevent obesity and associated comorbidities. The first step in this process requires a precise and detailed visualization of the lymphatic network in healthy and inflamed adipose tissue. Here, we describe a rapid, inexpensive, and efficient method that allows to label and analyze lymphatic and blood vessels. This approach takes advantage of the skin-draining brachial lymph node localization within the subcutaneous adipose tissue. The lymphatic arborization of this tissue can be revealed by injecting fluorochrome-conjugated lectins subcutaneously. Moreover, the in vivo labeling approach provides a way to evaluate lymphatic vessel density and functions. Coupled to blood vessel, adipocyte and immune cell staining, the protocol allows for high-resolution mapping of the subcutaneous adipose tissue by 3D imaging.

Introduction

The lymphatic circulatory system plays a crucial role in the maintenance of tissue homeostasis and the induction of efficient immune responses. Lymphatic vessels run parallel to blood vessels and carry interstitial fluid, metabolites, and immune cells to the local draining lymph node (LN) and finally towards the venous circulation¹. Dysfunctional lymphatic drainage has been observed during infection, inflammation and metabolic diseases^2,3,4,5. The lymphatic vasculature is composed of small size vessels named lymphatic capillaries. Lymphatic capillaries are formed by a single layer of thin lymphatic endothelial cells (LECs) characterized by open junctions (“button-like” junctions) facilitating interstitial fluid, metabolites, and immune cells, mainly dendritic cells (DCs) and T cells, entry into the lymphatic capillary lumen⁵. Lymphatic capillaries merge into larger vessels named lymphatic collecting vessels. Lymphatic collectors are characterized by a layer of LECs surrounded by a muscle layer providing autonomous contractile tonus and maintaining fluid flow⁵. Moreover, collecting vessels possess valves assuring a unidirectional lymph flow.

The LECs of collectors and capillaries express a specific set of markers that distinguish them from blood endothelial cells (BECs). Among those factors, Prox1 is a transcription factor guiding LECs generation and is highly expressed in LECs while absent in BECs. The critical involvement of Prox1 in LECs biology was illustrated by the generation and analysis of Prox1-deficient mice⁶. Prox1 heterozygous mice have a defective lymphatic vasculature development characterized by reduced lymphatic vessel density and increased vascular permeability⁶. LECs highly express VEGFR3, Podoplanin and CCL21⁵. Those markers are not found on BECs and allow to separately analyze the network of lymphatic and blood vessels. Lyve1 is selectively expressed by lymphatic capillaries while absent on collecting vessels⁵.

Three types of adipose tissue have been described based on their mitochondrial content and subsequent color. Mitochondria-rich thermogenic brown adipose tissue plays a key role during cold exposure and is located in the interscapular region in mice^7,8. White and beige adipocytes have lower mitochondrial density and are mainly involved in energy storing in the form of lipid droplets. White and beige adipocytes are located in visceral and subcutaneous depots⁹.

Clinical observations established a link between obesity and lymphatic dysfunction¹⁰. Obesity induces morphological changes of adipose tissue lymphatic vasculature and leads to an impaired lymph transport¹¹. Data obtained in pre-clinical models revealed that High Fat Diet (HFD) induces a lymphatic remodeling and obese mice have smaller lymph nodes and fewer number of lymphatic vessels¹². Nevertheless, the precise molecular mechanisms governing this phenotype remain to be elucidated. LECs involvement during obesity is further supported by observations in genetic models with impaired lymphatic vessel development. As discussed earlier, Prox1 heterozygous mice (Prox1^+/-) present an ill-functioning lymphatic system, and coincidently develop excessive visceral adipose tissue accumulation in comparison to Prox1 sufficient animals⁶. Interestingly, this adipose tissue phenotype is rescued by restoration of lymphatic function¹³. Together, these results have brought to light strong inter-connections between lymphatic vessels and the adipose tissue, which need further investigation.

In the context of inflammation, a hallmark of obesity, the altered expression of LEC and BEC markers compromises the analysis of these cells via classical antibody staining^14,15. Genetic models to label specifically LECs and BECs have been developed and allow to palliate this problem^16,17,18,19. However, the usage of genetic reporter lines requires multiple steps of breeding and considerably increases the length and cost of a project. Thus, we propose to use fluorochrome-conjugated lectin injections to investigate blood and lymphatic circulatory systems in the subcutaneous adipose tissue, a simple and relatively non-expensive approach. Lectin conjugated to various fluorochromes are commercially available and can be injected intravenously to label blood vessels, or subcutaneously to label the skin-draining lymphatic vessels embedded in the subcutaneous adipose tissue. This approach relies on the use of separate fluorochrome-lectin conjugates for each injection and allows the distinct labeling of each vasculature. This method is also compatible with the use of genetic models to label the lymphatic or blood vasculature network. Importantly, it provides multiple readouts to analyze the overall health status of the subcutaneous adipose tissue and the blood and lymphatics vasculatures perfusing it. This procedure could be easily applied to analyze the lymphatic and blood vasculature networks during acute and chronic skin diseases including psoriasis and infections.

Protocol

All animal experimentation was performed in accordance with local ethical committees.

NOTE: Prox1-cre-ERT2 (Prox1tm3(cre/ERT2)Gco/J, Jax #022075) and Rosa26-LSL-tdTomato (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J, Ai9, Jax #007914) were obtained from The Jackson Laboratory and crossed to obtain the inducible lymphatic reporter mouse line Prox1-cre-ERT2::tdTomato. Mice were backcrossed to C57BL/6 background for 10 generations. Six-week-old Prox1-cre-ERT2::tdTomato male mice received tamoxifen diet for 3 weeks. Tamoxifen diet from Envigo Teklad (diet no. TD.130857; 500 mg/kg) was used. Experiments were performed in 12-14-week-old mice. This protocol is applicable to mice of any age, sex or strain.

1. Material preparation

1. Sterilize scissors, forceps and dissecting pins using 70% ethanol.
2. Prepare two 1 mL syringes with 25 to 27 gauge needles. For subcutaneous injection we recommend using a micro-syringe to inject 10 μL in the upper footpad.
3. In a plastic 1.5 mL tube, prepare 200 µL of DyLight 488-conjugated lectin diluted in sterile PBS at a final concentration of 100 μg/mL.
4. In another plastic, 1.5 mL tube prepare 100 µL of DyLight 649-conjugated lectin diluted in sterile PBS at a final concentration of 100 μg/mL.
5. Prepare a 6-well plate containing PBS and keep it on ice.
6. Prepare a solution of 4% paraformaldehyde and 30% sucrose.

2. Labeling of subcutaneous adipose tissue blood and lymphatic vessels.

1. Anesthetize the mouse by inhalation of 5% isoflurane. Assess anesthesia depth by firmly pinching the animal’s paw to ensure that the animal is not harmed during the procedure. Anesthesia should be maintained until the end of the lectin injection steps or until euthanasia.
2. Inject 100 µL of DyLight 488-conjugated lectin intravenously in the tail vein to label the blood vasculature. Wait 15 minutes before proceeding to tissue harvesting.
3. Using a different syringe, inject 10 µL of DyLight 649-conjugated lectin subcutaneously on the upper footpad of the animal to label the draining lymphatic vessels. Wait 15 minutes before proceeding to tissue harvesting.
4. Euthanize the mouse by cervical dislocation or exposure to CO₂ 15 minutes post-injection.

3. Harvesting of subcutaneous adipose tissue

1. Lay the mouse on its back on a dissection board.
2. Sterilize the fur of the mouse using 70% ethanol.
3. Lift the skin of the flank using forceps and make a transversal incision to expose the brachial fat pad.
4. Gently pull on the skin to dissociate it from the brachial adipose tissue depot, thus revealing the entire subcutaneous brachial adipose tissue containing the lymph node and the lymphatic collector vessel.
5. Using forceps and scissors, gently remove subcutaneous fat depots and transfer them to a dish containing cold PBS. For best results, we recommend removing the fat depots as one single piece.
6. From here on out, protect the tissue from light.

4. Tissue fixation

1. Submerge the harvested tissue in a solution containing 4% paraformaldehyde and 30% sucrose.
2. Incubate the tissue in this solution at least overnight before preparing it for imaging.

5. Staining and imaging

1. For optimal results, perform tissue clearing and 3D confocal acquisition as described by Gilleron and colleagues²⁰. We recommend using a light sheet microscope for analysis of large tissues. Additional staining can be performed during the clearing process.
2. To achieve best tissue mapping, use of the following antibodies:
   For adipocytes: Perilipin
   For macrophages: CD68 and CD11b staining.
   For dendritic cells: MHC II and CD11b.
   For B cells: B220 (CD45R) staining.
   For T cells: CD3 staining.
   NOTE: This method is compatible with the use of genetic models to label immune cells.
3. For the analysis of the lymphatic collector vessel by intravital 2-photon microscopy, inject the lectin subcutaneously in the lower footpad and visualizing the popliteal lymphatic collecting vessel.

Results

To perform topological analysis of brachial adipose tissue blood and lymphatic vessel networks, we subcutaneously injected Alexa Fluor 649-conjugated lectin, and intravenously injected Alexa Fluor 488-conjugated lectin. The brachial adipose tissue was carefully excised, fixed, submitted to clearing protocol, and analyzed by whole-mount staining. A schematic representation of the procedure is included in Figure 1A. Blood vessels are labeled in green and lymphatics are in red. The brachial adi...

Discussion

This approach provides efficient and robust labeling of the blood and lymphatic vasculatures of the subcutaneous adipose tissue. The separate analysis of blood and lymphatic endothelial networks might unravel pathological mechanisms affecting one or both of the circulatory systems during obesity or other pathological conditions. This protocol aims to analyze the architecture of the vascular systems, their interaction with stromal and immune cells, and their functionality during health and disease.

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
Lectin DyLight 649	Vector Labs	DL-1178-1	Described in protocol
Lectin DyLight 488	Vector Labs	DL-1174	Described in protocol
Paraformaldehyde	VWR Chemicals	9713.1000
Sucrose	Euromedex	CAS Number 57-50-1
Anti-Podoplanin	AngioBio	11-033	Dilution : 1/50
Lectin DyLight 594	Vector Labs	DL-1177	Described in protocol
Anti-MHCII (Clone M5/114.15.2)	Biolegend	107618	Dilution : 1/100
Anti-CD11b (Clone M1/70)	Biolegend	101218	Dilution : 1/100
Anti-CD68 (Clone FA.11)	Biolegend	137004	Dilution : 1/100
Anti-B220 (Clone RA3-6B2)	Biolegend	103225	Dilution : 1/100
Anti-Perilipin (Clone PERI 112.17)	Progen	651156	Dilution : 1/50
Anti-CD3 (Clone 17A2)	Biolegend	100210	Dilution : 1/100